Business Context and Reporting Period
This Form 8-K Current Report, dated June 26, 2012, details a material definitive agreement entered into by NanoViricides, Inc. (Nevada corporation) with Seaside 88, LP. The filing reports on a securities offering structured to raise capital through the sale of Series C Convertible Preferred Stock.
Key Financial Metrics and Transaction Details
- Total Offering Size: Up to $5,000,000 via the sale of 5,000 shares of Series C Convertible Preferred Stock at $1,000 per share.
- Initial Closing Proceeds: $2,500,000 raised on June 28, 2012, from the purchase of 2,500 shares.
- Estimated Expenses: Approximately $200,000 in offering expenses (placement agent and legal fees).
- Placement Fee: 6% of the gross purchase price paid to Midtown Partners & Co., LLC.
- Initial Conversion: 146.7916 shares of Series C Preferred Stock converted into 298,472 shares of Common Stock at a conversion price of $0.49181.
- Debt and Liquidity: The filing does not provide specific data on existing debt levels, cash flow, or overall liquidity beyond the proceeds from this transaction.
Material Changes and Transaction Structure
The primary material change is the entry into a Securities Purchase Agreement creating a two-closing structure:
- Initial Closing: Completed June 28, 2012, for $2,500,000.
- Subsequent Closing: Scheduled for ten business days after the conversion of Initial Closing shares, contingent on satisfaction of conditions precedent, for the remaining $2,500,000.
- Conversion Mechanics: Shares convert every 14 days. The conversion price is the lower of 85% of the 10-day VWAP or 88% of the prior day's VWAP. Conversions are subject to a "Floor" of $0.20 VWAP over 20 days and a "Share Limit" capping issuance at twice the volume of the preceding conversion.
Outlook, Risks, and Management Commentary
Management highlights several risks associated with the forward-looking statements in this report:
- Closing Conditions: Uncertainty regarding the Company's ability to satisfy conditions precedent for the Subsequent Closing in a timely manner or at all.
- Dilution: Substantial dilution to current stockholders due to the discount offered to Seaside 88, LP.
- Market Overhang: Potential market pressure from the resale of shares acquired by Seaside 88, LP.
- Regulatory Status: The offering is made pursuant to a shelf registration statement (Form S-3) declared effective on April 29, 2010.
Investor Verification Checklist
- Verify the satisfaction of conditions precedent required for the Subsequent Closing of $2,500,000.
- Monitor the Common Stock VWAP to determine if it remains above the $0.20 "Floor" required for future conversions.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and indemnification terms.
- Assess the impact of the 6% placement fee and estimated $200,000 in expenses on net proceeds.
- Track the volume of Common Stock traded to calculate potential dilution under the 15% trading volume conversion formula.